Sidecar Therapeutics

Sidecar Therapeutics is a private, early-stage biotechnology company based in San Diego focused on discovering small molecule therapies for fibrotic diseases. Publicly visible information on the company is limited, but third-party company databases describe it as active and venture-backed, and patent literature links the company to apoptosis signal-regulating kinase 1 (ASK1, MAP3K5) inhibitor programs. Its disclosed work appears to center on oral small molecule inhibitors intended for fibrosis-associated diseases, including non-alcoholic steatohepatitis and related liver fibrosis indications. The company appears to be operating in a preclinical drug discovery stage rather than in human clinical development. Because the company has maintained a relatively low public profile, much of the available evidence comes from patents and business registry sources rather than a detailed operating pipeline disclosure.